Review: Rosiglitazone increases risk for cardiovascular outcomes and mortality compared with pioglitazone in type 2 diabetes

被引：0
|
作者：
Deedwania, Prakash [1 ]
机构：
[1] Univ Calif San Francisco, Sch Med, Fresno, CA 93701 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2011年 / 155卷 / 04期
关键词：
D O I：
10.7326/0003-4819-155-4-201108160-02012
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus
    Irons, BK
    Greene, RS
    Mazzolini, TA
    Edwards, KL
    Sleeper, RB
    [J]. PHARMACOTHERAPY, 2006, 26 (02): : 168 - 181
  • [2] Rosiglitazone or pioglitazone in type 2 diabetes?
    de Vries, Corinne S.
    Russell-Jones, David L.
    [J]. BRITISH MEDICAL JOURNAL, 2009, 339
  • [3] Different Effects of Thiazolidinediones on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus: Pioglitazone vs Rosiglitazone
    Simo, Rafael
    Rodriguez, Angel
    Caveda, Elena
    [J]. CURRENT DRUG SAFETY, 2010, 5 (03) : 234 - 244
  • [4] EFFECTS OF PIOGLITAZONE AND ROSIGLITAZONE ON GLUCOSE AND THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES: A META-ANALYSIS
    Lee, J. K.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A497 - A497
  • [5] Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes
    Aubert, R. E.
    Herrera, V.
    Chen, W.
    Haffner, S. M.
    Pendergrass, M.
    [J]. DIABETES OBESITY & METABOLISM, 2010, 12 (08): : 716 - 721
  • [6] Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
    Rawshani, Aidin
    Rawshani, Araz
    Franzen, Stefan
    Sattar, Naveed
    Eliasson, Bjorn
    Svensson, Ann-Marie
    Zethelius, Bjorn
    Miftaraj, Mervete
    McGuire, Darren K.
    Rosengren, Annika
    Gudbjornsdottir, Soffia
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (07): : 633 - 644
  • [7] Systematic review: cardiovascular risk and mortality with rosiglitazone
    [J]. Reactions Weekly, 2020, 1791 (1) : 13 - 13
  • [8] Pioglitazone reduces cardiovascular risk in patients with type 2 diabetes
    Bierwirth, R. A.
    Dietlein, M.
    Franzen, C.
    Gruenerbel, A.
    Hofmann, C.
    Merke, J.
    Luebben, G.
    Karagiannis, E.
    [J]. DIABETOLOGE, 2008, 4 (07): : 542 - 548
  • [9] Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes
    Donnelly, R.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (07) : 1160 - 1169
  • [10] Rosiglitazone [Avandia] does not increase the risk of cardiovascular mortality and morbidity in patients with type 2 diabetes mellitus
    [J]. Reactions Weekly, 2008, 1206 (1) : 5 - 5
12345